Medical Treatment of Opoid Use Disorder (OUD)

Mike Bushey, MD, PhD Assistant Professor of Psychiatry Indiana University School of Medicine


PART 1: DEFINING & DIAGNOSING ADDICTION


ADDICTION leads to PERMANENT **BRAIN CHANGES** that **ALTER BEHAVIOR**


Behavior Can Be **DRIVEN**


THIRST \rightarrow DRINK HUNGER \rightarrow EAT EXHAUSTION \rightarrow SLEEP

Hunger









Behavior Can Be **LEARNED**


BEHAVIOR --> CONSEQUENCE



BEHAVIOR REWARD




USE OPIOID










Time \rightarrow

Behavior Can Be **DRIVEN**



DSM-V Criteria for Opioid Use Disorder (OUD)

- 1. Larger amounts or over a longer period than intended.
- 2. Unsuccessful efforts to cut down or control opioid use.
- 3. <u>Great deal of time</u> is spent to obtain, use or recover from opioids.
- 4. <u>Cravings</u> for opioids.
- 5. Failure to fulfill roles at work, school, or home.
- 6. <u>Social or interpersonal problems</u> caused by opioids.
- 7. <u>Activities are given up</u> or reduced because of opioid use.
- 8. Physically hazardous opioid use
- 9. Continued opioid use despite **physical or psychological consequences**
- 10. Tolerance.*
- 11. Withdrawal.*

* Don't count toward OUD diagnosis if patient is prescribed opioids

<u>For Diagnosis of OUD:</u> Mild: 2-3 present Moderate: 4-5 present Severe: 6 or more present


DSM-V Criteria for Opioid Use Disorder (OUD)

- Larger amounts or over a longer period than intended.
- In paired t Control Over Use 3
- Cravings for opioids. 4.
- Failure to fulfill roles at work, school, or home. Social oSocial regulation of the school of the second se 6.
- Physic Health Consequences
- ^{10.} WR Bysiologic Dependence

PART 2: TREATING ADDICTION

TREATMENT GOAL: **DECREASE** the **ODDS** the **ADDICTED BRAIN** will **CHOOSE** the **ADDICTED BEHAVIOR.**

Hypertension Treatment



STAGE OF TREATMENT

NIDA. Principles of Drug Addiction Treatment. 2012. McLellan et al., JAMA, 284:1689-1695, 2000 .

Treatment Modalities for SUDs

Psychosocial/behavioral

- Modalities
 - Cognitive Behavioral Therapy (CBT)
 - Motivational Enhancement Therapy (MET)

Pharmacotherapy

- Alcohol use disorder
 - naltrexone, acamprosate, disulfiram, topiramate
- Opioid use disorder
 - methadone, buprenorphine, naltrexone
- Tobacco use disorder
 - varenicline, bupropion, NRT
- Cocaine use disorder
 - Topiramate, naltrexone
- Methamphetamine use disorder
 - Bupropion/naltrexone

Treatment Modalities for SUDs


Psychosocial/behavioral

- Modalities
 - Cognitive Behavioral Therapy (CBT)
 - Motivational Enhancement Therapy (MET)

Pharmacotherapy


- Alcohol use disorder
 - naltrexone, acamprosate, disulfiram, topiramate
- Opioid use disorder
 - methadone, buprenorphine, naltrexone
- Tobacco use disorder
 - varenicline, bupropion, NRT
- Cocaine use disorder
 - Topiramate, naltrexone
- Methamphetamine use disorder
 - Bupropion/naltrexone


Readiness for Change




Medication for Opioid Use Disorder (MOUD)

- Improves patient survival
- Increases retention in treatment
- Decreases illicit opioid use
- Decreases criminal activity
- Increase patients' ability to gain and maintain employment
- Improves birth outcomes among pregnant women
- Lowers a person's risk of contracting HIV or hepatitis C







FULL AGONIST (Methadone)







FULL AGONIST PARTIAL AGONIST(Methadone) (Buprenorphine)








FULL AGONISTPARTIAL AGONISTANTAGONIST(Methadone)(Buprenorphine)(Naltrexone)













Kakko, et al. The Lancet 361, no. 9358 (2003): 662-68.



Haight, et al. The Lancet 393, no. 10173 (2019): 778-90.



Haight, et al. *The Lancet* 393, no. 10173 (2019): 778-90.